– CNBC
JP Morgan Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $65
JP Morgan analyst Eric Joseph downgrades Mirati Therapeutics (NASDAQ:MRTX) from Overweight to Neutral and lowers the price target from $94 to $65.
Related Posts
Aytu BioPharma Announces Approval Of The Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla
This McDonald’s Analyst Begins Coverage With $288 Forecast; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
2 High Yielding Cannabis REITs To Benefit From State Legalization In November
As we head into the November midterm elections, states such as Maryland, Missouri, Arkansas, North Dakota and South Dakota are preparing to vote on the legalization of recreational marijuana.